Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NovaBridge Biosciences ( (NBP) ) has issued an update.
On April 7, 2026, NovaBridge Biosciences reported its full-year 2025 results, underscoring a strategic shift into a global biotech platform built around two mid-stage, potentially class-leading programs, givastomig for gastric cancer and VIS-101 for wet AMD. The company highlighted a strengthened leadership bench, expanded board and advisory structures, and a $210.8 million cash position at year-end 2025, which management expects will fund operations through 2028.
In clinical development, givastomig produced robust and durable Phase 1b responses in first-line metastatic gastric cancer, with data released in January 2026 supporting potential U.S. accelerated approval and a Phase 3 start targeted around late 2026. VIS-101 delivered positive Phase 2a data in February 2026 in treatment-naïve wet AMD patients, with strong durability signals and a Phase 2b program planned for the second half of 2026, positioning NovaBridge as an emerging player in oncology and ophthalmology with a pipeline that could materially reshape its long-term growth profile.
The most recent analyst rating on (NBP) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on NovaBridge Biosciences stock, see the NBP Stock Forecast page.
Spark’s Take on NBP Stock
According to Spark, TipRanks’ AI Analyst, NBP is a Neutral.
The score is primarily held back by deteriorated financial performance (no 2024 revenue, persistent losses, and ongoing cash burn) despite low leverage. Technicals are mildly bearish with price below key moving averages and a slightly negative MACD, while valuation is largely neutral because negative earnings make the P/E less informative and no dividend support is shown.
To see Spark’s full report on NBP stock, click here.
More about NovaBridge Biosciences
NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology platform company focused on developing innovative biologic medicines, including bispecific antibodies and retinal therapies. The company’s lead assets are givastomig, a Claudin 18.2-directed bispecific antibody for gastric cancer, and VIS-101, a VEGF-A x ANG-2 inhibitor for wet age-related macular degeneration, advanced through a hub-and-spoke structure that includes its Visara subsidiary.
Average Trading Volume: 793,721
Technical Sentiment Signal: Sell
Current Market Cap: $279M
For a thorough assessment of NBP stock, go to TipRanks’ Stock Analysis page.